Imaging of Arthropathy in Boys With Hemophilia in China
Study Details
Study Description
Brief Summary
Hemophilia is a genetic condition characterized by marked phenotypic heterogeneity. Bleeding into a joint is the single most important risk factor for the development of hemophilic arthropathy (HA). It is thought that clinical and imaging manifestations of HA are at least partially attributable to genetic polymorphisms unrelated to the hemophilia genotype. Identifying and characterizing biologic factors that could explain differences in susceptibility to joint degeneration of patients with hemophilia would help stratify patients according to the risk of degeneration of their joints and develop personalized therapeutic and prophylactic strategies. This study is conducted in China.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This will be a 3-year prospective cohort study conducted in a single centre (Beijing Children's Hospital, BCH, China) with a 2-year follow-up of patients Index joints (ankles, elbows and knees) of young Chinese boys with hemophilia A will be evaluated as follows: physical examination every 6 months using the Hemophilia Joint Health Score [HJHS], ultrasound imaging (gray-scale and color Doppler ultrasound [US]), and by laboratory (serum) at baseline, at 6, and 24 months. Magnetic resonance imaging (MRI) scans of index joints will be obtained at baseline, and 24 months. Features that will be captured either quantitatively or semantically in the imaging scans will be aggregated to generate "imaging phenotypes" which will be associated with clusters of co-expressed genes (metagenes) and clinical data.
Study Design
Outcome Measures
Primary Outcome Measures
- Annualized total index joint bleeding rates (AJBRs) [Between baseline and 24 months]
AJBRs will be calculated from prospectively collected joint bleeding logs and clinic records.
Secondary Outcome Measures
- Number of participants with joint inflammation [At baseline, 6 months and 24 months]
Assessed by ultrasound
- Number of participants with joint inflammation [Between baseline and 24 months]
Assessed by MRI of the joints
- Number of participants with joint damage [At baseline, 6 months and 24 months]
Assessed by ultrasound
- Number of participants with joint damage [Between baseline and 24 months]
Assessed by MRI of the joints
- Number of participants with clinical arthropathy [Every 6 months]
Assessed by the Hemophilia Joint Health Score tool (HJHS), version 2.1 - Joint score range: 0 (normal) to 16 (worse outcome).
- Presence of inflammatory biomarkers in plasma [At baseline, 6 months and 24 months]
Measured by ELISA (enzyme-linked immunosorbent assay)
- Internal MRI-based soft tissue score change [Between baseline and 24 months]
Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)
- Internal MRI-based osteochondral tissue score change [Between baseline and 24 months]
Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Hemophilia A with baseline FVIII levels of <2%
-
Clinical history of ≥ 50 exposure days to FVIII prior to the study start.
-
On-demand treatment, prophylaxis FVIII infusions or treatment with plasma-derived products for >3 months prior to enrollment into the study.
Exclusion Criteria:
-
History of FVIII inhibitor (titer >0.6 Bethesda Units [BU])
-
Chronic renal failure (serum creatinine >2.0 mg /dL).
-
Chronic liver disease (alanine aminotransferase [ALT] >200 U/L).
-
Clinically documented immunodeficiency.
-
Anticipation of need for major surgery during the study period.
-
Association of diseases known to mimic or cause joint diseases such as symptomatic human immunodeficiency virus (HIV) infection, juvenile idiopathic arthritis, and metabolic bone diseases.
-
Social barriers for participation in the study such as long distance between home and the comprehensive care centre, and documented track record of non-compliance to therapies or participation in clinical studies.
-
Neuro-developmental/behavioral problems.
-
Contraindications to MR imaging (presence of heart pacemakers, metallic foreign bodies in the eye, aneurysm clips, severe claustrophobia).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Children's Hospital | Beijing | China |
Sponsors and Collaborators
- Andrea Doria
- Beijing Children's Hospital, Baxalta US Inc.
Investigators
- Principal Investigator: Andrea Doria, MD, The Hospital for Sick Children
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1000058500